NOVAVAX INC Revenue from Contract with Customer, Excluding Assessed Tax
NOVAVAX INC (NVAX) reported Revenue from Contract with Customer, Excluding Assessed Tax of $56.70 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-06
- NOVAVAX INC revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $56.70M, a 76.30% decline year-over-year.
- NOVAVAX INC revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $139.51M, a 79.07% decline year-over-year.
- NOVAVAX INC revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $147.14M, a 66.61% increase year-over-year.
- NOVAVAX INC revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $70.44M, a 16.64% decline year-over-year.
- NOVAVAX INC revenue from contract with customer, excluding assessed tax for fiscal 2025 was $1.12B, a 64.69% increase from fiscal 2024.
- NOVAVAX INC revenue from contract with customer, excluding assessed tax for fiscal 2024 was $682.16M, a 30.65% decline from fiscal 2023.
- NOVAVAX INC revenue from contract with customer, excluding assessed tax for fiscal 2023 was $983.71M, a 50.36% decline from fiscal 2022.
- NOVAVAX INC revenue from contract with customer, excluding assessed tax for fiscal 2022 was $1.98B.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 3 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $56.70M 10-Q · filed 2026-08-06 | $196.21M 10-Q · filed 2026-08-06 | $343.35M derived: sum of 3 quarters · filed 2026-08-06 | $413.80M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | $139.51M 10-Q · filed 2026-05-06 | $286.65M derived: sum of 2 quarters · filed 2026-05-06 | $357.10M derived: sum of 3 quarters · filed 2026-05-06 | $596.34M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | $147.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $217.58M derived: sum of 2 quarters · filed 2026-02-26 | $456.82M derived: sum of 3 quarters · filed 2026-08-06 | $1.12B 10-K · filed 2026-02-26 | |
| 2025-09-30 | $70.44M 10-Q · filed 2025-11-06 | $309.69M derived: sum of 2 quarters · filed 2026-08-06 | $976.34M 10-Q · filed 2025-11-06 | $1.06B derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | $239.24M 10-Q · filed 2026-08-06 | $905.89M 10-Q · filed 2026-08-06 | $994.21M derived: sum of 3 quarters · filed 2026-08-06 | $1.08B derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | $666.65M 10-Q · filed 2026-05-06 | $666.46M 10-Q · filed 2025-05-08 | $754.97M derived: sum of 2 quarters · filed 2026-05-06 | $839.48M derived: sum of 3 quarters · filed 2026-05-06 | $1.25B derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $88.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $172.82M derived: sum of 2 quarters · filed 2026-02-26 | $588.31M derived: sum of 3 quarters · filed 2026-02-26 | $682.16M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $84.51M 10-Q · filed 2025-11-06 | $500.00M derived: sum of 2 quarters · filed 2025-11-06 | $593.85M 10-Q · filed 2025-11-06 | ||
| 2024-06-30 | $415.48M 10-Q · filed 2025-08-06 | $509.34M 10-Q · filed 2025-08-06 | |||
| 2024-03-31 | $93.86M 10-Q · filed 2025-05-08 | ||||
| 2023-12-31 | $983.71M 10-K · filed 2026-02-26 | ||||
| 2022-12-31 | $1.98B 10-K · filed 2025-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |